Bains, Elizabeth
June 2007
ICIS Chemical Business;6/4/2007, Vol. 2 Issue 69, p11
Trade Publication
This article focuses on the promise of the European Union (EU) to tackle the growing problem of counterfeited medicine. At a pharmaceuticals forum in May 2007, EU officials said that while fake medicine was less widespread in Europe than in Africa and Asia, it was on the rise with internet sales of so-called lifestyle drugs such as Viagra and dietary pills. The World Health Organization said that fake medicine accounts for 10-30% of total drug sales in Latin America, Africa and Asia.


Related Articles

  • Health And Harm. Clift, Charles // World Today;Dec2010, Vol. 66 Issue 12, p11 

    The article looks at counterfeit medicines, focusing on public health concerns and legal issues surrounding the theft of intellectual property. Efforts to fight counterfeiting in the pharmaceutical industry are discussed, including the formation of the International Anti-Counterfeiting Coalition...

  • Europe Stumbles over New Pharma Rules. O'Donnell, Peter // BioWorld International;11/5/2008, Vol. 13 Issue 45, p5 

    The article reports on the postponement of European Union (EU) plans to update pharmaceutical legislation after Günter Verheugen, the European commissioner for industry responsible for the proposals to combat counterfeiting, withdrew in the face of opposition from colleagues. Concerns that...

  • Counterfeit drugs a growing worldwide danger. Buono, Drew // Drug Store News;6/23/2008, Vol. 30 Issue 7, p60 

    The article reports on the effect of the increased percentage of counterfeit drugs on public health and pharmaceutical industry in the U.S. It is stated that counterfeiting may have caused the deaths of 81 patients who died after being treated with contaminated heparin, a blood-thinning drug. To...

  • Report Claims China Remains Main Source of Counterfeit Goods.  // Security: Solutions for Enterprise Security Leaders;Oct2014, Vol. 51 Issue 10, p12 

    The article offers information on the statement of the International Hologram Manufacturers Association (IHMA) regarding the report from the European Union (EU), the Japan Patent Office and the U.S. Department of Homeland Security which claims China as the primary source of counterfeit goods.

  • EGA position on the EC's proposal for a falsified medicines directive. Markova, Ilina // Pharmaceutical Technology Europe;Oct2010, Vol. 22 Issue 10, p51 

    The article discusses the adoption of a European Commission (EC) proposal for a Directive on the falsification of medicines by the European Generic Medicines Association (EGA). It explores two provisions relevant to the European generic medicines industry identified by the EGA. It cites EGA's...

  • Falsified Medicines Directive Takes Shape in Europe. Milmo, Sean // Pharmaceutical Technology Europe;Jan2013, Vol. 25 Issue 1, p16 

    The article presents information on the approval of the legislation related to Falsified Medicines Directive (FMD) by the European Union (EU) in order to tackle the growing problem of counterfeit medicines. The other objective of the legislation is to deal with the increasing amounts of...

  • Taking the fight to global fakers. Chadwick, Philip // Packaging News;Feb2012, p25 

    The article offers information on the efforts made by the European Union (EU) to eliminate the production of counterfeit medicines in pharmaceutical industry. It reports that the EU has released the EU regulation Falsified Medicines Directive to identify counterfeiters in the industry. It...

  • Curbing counterfeits in the EU. Milmo, Sean // Pharmaceutical Technology Europe;Jul2011, Vol. 23 Issue 7, p14 

    The article discusses the approval of the European Union's Falsified Medicines Directive (FMD) which aims to combat counterfeit medicines in Europe. It states that the legislation is yet to be polished with the efforts of the European Commission (EC) which was assigned by the EU to implement the...

  • Purely medicinal? Richards, Tessa // BMJ: British Medical Journal (International Edition);3/29/2008, Vol. 336 Issue 7646, p693 

    The author reflects on a European Union commission legislative proposal which would allow pharmaceutical companies to provide information on their prescription drugs directly to the public. She suggests that physicians and other members of society should take the time to respond to the proposal....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics